Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS10015691HBVENSG00000134460.19protein_codingIL2RANoNo3559P01589
Q5W005
TVIS10026184HBVENSG00000134460.19protein_codingIL2RANoNo3559P01589
Q5W005
TVIS30011403HIVENSG00000134460.19protein_codingIL2RANoNo3559P01589
Q5W005
TVIS30004372HIVENSG00000134460.19protein_codingIL2RANoNo3559P01589
Q5W005
TVIS30010128HIVENSG00000134460.19protein_codingIL2RANoNo3559P01589
Q5W005
TVIS20032371HPVENSG00000134460.19protein_codingIL2RANoNo3559P01589
Q5W005
TVIS20040966HPVENSG00000134460.19protein_codingIL2RANoNo3559P01589
Q5W005
TCGA Plot Options
Drug Information
GeneIL2RA
DrugBank IDDB16411
Drug NameCamidanlumab tesirine
Target IDBE0000658
UniProt IDP01589
Regulation Typeantibody
PubMed IDs32521310; 32912922
CitationsGoldberg AD, Atallah E, Rizzieri D, Walter RB, Chung KY, Spira A, Stock W, Tallman MS, Cruz HG, Boni J, Havenith KEG, Chao G, Feingold JM, Wuerthner J, Solh M: Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study. Leuk Res. 2020 Aug;95:106385. doi: 10.1016/j.leukres.2020.106385. Epub 2020 Jun 7.@@Zammarchi F, Havenith K, Bertelli F, Vijayakrishnan B, Chivers S, van Berkel PH: CD25-targeted antibody-drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity. J Immunother Cancer. 2020 Sep;8(2). pii: jitc-2020-000860. doi: 10.1136/jitc-2020-000860.
GroupsInvestigational
Direct ClassificationPeptides
SMILES
Pathways
PharmGKB
ChEMBL